Erythropoietin in kidney disease and type 2 diabetes [8]

New England Journal of Medicine

Volumn 364, Issue 4, 2011, Pages 384-

  Locatelli, Francesco ^a   Del Vecchio, Lucia ^a   Casartelli, Donatella ^a  

^a A MANZONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

BLOOD LEVEL; CARDIOVASCULAR DISEASE; GENERAL PRACTITIONER; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY DISEASE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT RESPONSE; ANEMIA; CHRONIC KIDNEY FAILURE; NOTE; RISK;

ANEMIA; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; ERYTHROPOIETIN; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; RISK;

EID: 79251508353     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1012157     Document Type: Letter

References (1)

1. Locatelli F, Aljama P, Canaud B, et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transplant 2010;25:2846-50.